Kornimate/medical-research-clean huggingface dataset:
multi-center study of deep learning ai in breast mass

Conditions: Breast Neoplasms

Summary: this multi-center study intends to evaluate the value of the detection and differential diagnosis of breast mass using deep learning ai-based real-time ultrasound examination.

as the most common cancer expected to occur all over the world, extensive population screening plays a very important role in the early diagnosis and prognosis of the breast cancer. x-ray and ultrasound are the most commonly used screening methods, and ultrasound is especially important for asian women with dense breasts. however, ultrasound is greatly affected by the operator's skill and experience, and the diagnostic accuracy varies greatly. artificial intelligence (ai) is a new method emerging in recent years, active in many medical fields and can effectively improve the diagnostic efficiency. however, previous researches on the application of ai in ultrasound are focused on single or multi-modality static ultrasound images. this multi-center study intends to evaluate the value of the detection and differential diagnosis of breast mass using deep learning ai-based real-time ultrasound examination.

Eligibility criteria:
inclusion criteria: 1. females who undergo ultrasound examination for a complaint of breast lesion; 2. the breast lesion that will obtain definite pathological diagnosis or follow-up at least two years. exclusion criteria: 1. the breast lesion that has received cnb or fna; 2. the breast cancer patient who has received neoadjuvant chemotherapy.
evaluation of blood sampling from a pre-existed peripheral intravenous catheter line

Conditions: Emergencies

Summary: background: peripheral intravenous catheter (pivc) is a frequently used device for intravascular access. it is usually indicated to administer intravenous fluid and medications. however, the investigators could possibly utilize this line for blood sampling even after using it as a fluid port.

aims: to investigate the quality of previously flushed pivc sample and the effectiveness of the withdrawal technique. methodology: study will be held in king fahad university hospital during a year after obtaining the irb approval. selection of study participants will be depending on their health status and the investigators will exclude pediatric participants. two blood samples will be collected from participants. first one is after the insertion of the intravenous peripheral line. the second is after fluid infusion through the same line. samples will be sent to the laboratory then. results will be collected and analyzed. the importance of the research: if this type of sampling can be standardized , this means there will be less insertions to the patients, less adverse effects in relation to the number of insertions, fast and preexisted intravascular access for sampling so the time can be saved in critical conditions.

Eligibility criteria:
inclusion criteria: * it will include healthy adult volunteers. exclusion criteria: * pediatric patients and critically ill patients will be excluded from the study
amyloid-beta pet imaging with 18f-92 in alzheimer's disease

Conditions: Alzheimer's Disease

Summary: alzheimer's disease is a neurodegenerative disease. numerous studies have reported that β-amyloid (aβ) is an important marker for the diagnosis of ad. 18f-92 molecular probe is a novel molecularly targeted imaging agent, which can rapidly penetrate the blood-brain barrier and has high affinity and selectivity for aβ protein. in this study, 18f-92 pet/ct was used to monitor the regional distribution and the degree of deposition in patients with alzheimer's disease, and compared with clinical symptoms (neuropsychometry) to evaluate its application value in the diagnosis of ad.

healthy volunteers as well as patients meeting alzheimer's criteria will be recruited for this study. we will use pet/ct imaging technology to scan each participant's whole body or head and collect image data for analysis to evaluate the distribution and metabolism of 18f-92 in the subject's body. time from drug injection to scan completion is approximately 1 hour.

Eligibility criteria:
inclusion criteria: * patients or their families complain of significant memory impairment; * objective memory impairment (e.g., tests of article identification, recall, delayed memory); * meets alzheimer's criteria for dsmiv and nincds-adrda; * be able to obtain complete diagnosis and treatment records and be able to carry out long-term follow-up; * signed written consent. exclusion criteria: * nervous system diseases: including brain tumors, craniocerebral trauma, multiple sclerosis, epilepsy, etc.; * psychiatric disorders: including anxiety disorder, affective disorder, severe psychosis, or drug-induced psychosis; * pregnancy or lactation.
investigation of the impact of burn injury on parents

Conditions: Burns; Parents

Summary: burn injuries are related to longer hospital stay. patients who have a burned child are affected prolonged hospitalization. social life and quality of life are affected by burn injuries. therefore, the aim of this study is to investigate the effects of burn injury on parents.

pediatric burn injuries is commonly seen. burn injuries are extended from minor injuries to severe injuries. the severity of burn injury may affect burn related complications such as scar tissue and duration of hospitalization. this process extremely affect parents. although parents are part of this prolonged treatments process, there is no study that evaluated of the impact of burn injury on parents. therefore, the aim of this study is to investigate the effects of burn injury on parents.

Eligibility criteria:
inclusion criteria: * parents who have a burned child * parents who have a volunteer exclusion criteria: * parents who have no confirm to participate this study

Keywords: burn injury quality of life scar
cimr neuromuscular research biobank

Conditions: Neuromuscular Diseases; Neuromuscular Disorder; Neuromuscular Diseases in Children

Summary: the purpose of this research repository is to collect, store, and share with other researchers any tissues that subjects with all types of neuromuscular disease are willing to donate. these samples will be stored at virginia commonwealth university (vcu) and will be used for future research with this population.

the study involves collection of medical information about research participants and their families. no identifying information about family members will be collected. research participants will be asked for any general knowledge they have related to possible neurological disorders. research participants are also given the opportunity to provide blood, skin cells, urine, saliva, fecal matter, muscle tissue, cells, dna and/or rna samples. before any study procedures take place, the informed consent form will be provided and reviewed with potential research participants in detail. potential research participants will have an opportunity to ask additional questions before starting any study procedures.

Eligibility criteria:
inclusion criteria: * willing and able to give informed consent * positive diagnosis or suspected diagnosis of neuromuscular disease, or * family history of neuromuscular disease, or * healthy volunteer * age neonates-75 exclusion criteria: * unwilling to sign consent

Keywords: neuromuscular research repository biobank neuromuscular disorder
the empower study evaluating multiparameter gene testing as a predictor of short term endocrine therapy response in hormone receptor positive breast cancers

Conditions: Breast Cancer

Summary: evaluating multiparameter gene testing as a predictor of short term endocrine therapy response in hormone receptor positive breast cancers

the clinical trial will be a prospective, two strata, non-blinded, single institution, health canada approved, window of opportunity trial with 2 weeks of pre-surgical endocrine therapy using either anastrozole or tamoxifen. tissue from the initial biopsy and from surgery will be sent for ki67 analysis using the nanostring® assay.

Eligibility criteria:
inclusion criteria: * any patient with histologically confirmed newly diagnosed operable er+, her2 negative invasive carcinoma on diagnostic core biopsy that has a radiographic size ≥ 1.5 cm * histology has to be ductal, lobular or mixed * surgery date planned in the next 2-6 weeks * negative pregnancy test if of child baring potential * post-menopausal status verified by fsh and estradiol (with 6 months of amenorrhea) exclusion criteria: * previous treatment with endocrine therapy, chemotherapy or chest wall radiation within last 6 months * known metastatic or recurrent breast cancer.

Keywords: breast
whole body vibration effects on energy expenditure in obese adolescents

Conditions: Obesity

Summary: the main aim of the present study is to evaluate in a group of adolescents with obesity, hospitalized for a period of integrated metabolic rehabilitation (calorie restriction, aerobic physical activity, psychological counseling, nutritional re-education) lasting 3 weeks, the effects produced from a period of training with vibration stimulation on vibration platforms (whole body vibration exercise \[wbve\]) on the resting energy expenditure (ree), assessed through indirect calorimetry. the results will be compared with those obtained in a control group, subjected to integrated metabolic rehabilitation alone. secondary aims of the study are to evaluate the effects of training with wbve also on cardiovascular and musculoskeletal parameters, evaluated through specific functional tests, comparing them with those obtained in the control group.

the main aim of the present study is to evaluate in a group of adolescents with obesity, hospitalized for a period of integrated metabolic rehabilitation (calorie restriction, aerobic physical activity, psychological counseling, nutritional re-education) lasting 3 weeks, the effects produced from a period of training with vibration stimulation on vibration platforms (whole body vibration exercise \[wbve\]) on the resting energy expenditure (ree), assessed through indirect calorimetry. the results will be compared with those obtained in a control group, subjected to integrated metabolic rehabilitation alone. secondary aims of the study are to evaluate the effects of training with wbve also on cardiovascular and musculoskeletal parameters, evaluated through specific functional tests, comparing them with those obtained in the control group.

Eligibility criteria:
inclusion criteria: * male sex * age range 13-18 years * obesity (body mass index standard deviation score \> 2) * hospitalization for a multidisciplinary program of integrated metabolic rehabilitation at the division of auxology, s. giuseppe hospital, istituto auxologico italiano, irccs, piancavallo, italy exclusion criteria: * presence of cardiovascular, psychiatric, and musculoskeletal pathologies * absence of signed written consent

Keywords: resting energy expenditure body vibration body composition functional tests
apelin levels and g212a polymorphism of apelin receptor (apj)

Conditions: Obesity; Insulin Resistance; Diabetes Mellitus Type 2

Summary: the aim of this study is to investigate serum apelin levels as well as their possible association with g212a polymorphism of the apelin receptor in obese children and adolescents. so far apelin has been reported to be involved in the pathophysiology of various heart diseases such as cardiomyopathies and heart failure. according to recent reports in adults apelin seems to be associated with impaired glucose metabolism, particularly in newly diagnosed diabetes type 2 patients. obesity is associated with insulin resistance and compensatory hyperinsulinemia leading to diabetes mellitus type 2 even in youngsters. the researchers will try to investigate the role of this new adipokine in order to early detect and to prevent similar entities in childhood obesity.


Eligibility criteria:
inclusion criteria: * obese children and adolescents (aged 2-16 years old) exclusion criteria: * chronic diseases * hypothyroidism * medication
comparison of pdt combination with ranibizumab vs. ranibizumab monotherapy in persistent pcv with initial loading dose

Conditions: Age-related Macular Degeneration

Summary: the aim of this study is to compare the efficacy of early intervention of pdt combination compared with consecutive monthly treatment of intravitreal ranibizumab injections in pcv patients showing insufficient response with initial loading dose.

pcv is generally recognized as a subtype of wet amd characterized by the presence of aneurysmal orange-red polypoidal lesions with or without branching vascular network (bvn) in the choroidal vasculature as observed on indocyanine angiography (icga), representing 13% to 54.7% of newly diagnosed patients with neovascular amd. fifty percent of pcv had persistent leakage or recurrent bleeding with poor visual outcome, if left untreated. and in the everest study has shown that synergistic effects of anti-vegf and vpdt combination: vpdt strongly regress polyp and anti-vegf control to up-regulation of vegf induced by vpdt compared to ranibizumab monotherapy in newly diagnosed pcv patients. additionally, combination offers an opportunity for individualized treatment with potentially fewer treatments and less costs. therefore, the aim of this study is to compare the efficacy of early intervention of pdt combination compared with consecutive monthly treatment of intravitreal ranibizumab injections in pcv patients showing insufficient response with initial loading dose.

Eligibility criteria:
inclusion criteria: 1. age equal to or older than 50 years 2. insufficient responder to ranibizumab tx 3. icga-confirmed pcv 4. bcva letter score of 73 to 24 using early treatment of diabetic retinopathy study charts 5. ability to provide written informed consent and comply with study assessments for the full duration of the study exclusion criteria: 1. prior treatment with other anti-vegf treatments in the study eye. 2. prior treatment with other anti-vegf treatments within 3 months prior to visit 1 in the non-study eye. 3. prior treatment with verteporfin within 6 months prior to visit 1 in the study eye. 4. prior treatment with verteporfin within 7 days prior to visit 1 in the non-study eye. 5. previous subfoveal focal laser photocoagulation involving the foveal center in the study eye 6. previous submacular surgery in the study eye 7. a history of angioid streaks, presumed ocular histoplasmosis syndrome, or pathologic myopia 8. experienced rpe tear, retinal detachment, macular hole, or uncontrolled glaucoma 9. previous participation in a clinical trial involving anti-angiogenic drugs 10. intraocular surgery: 2 months before visit 1 in the study eye. 11. previous participation in any studies of investigational drugs 12. administration of periocular, intravitreal, or systemic corticosteroid in the previous 3 months.
development of a screening tool for difficult embryo transfers

Conditions: Infertility

Summary: this study aims to investigate the accuracy of a proposed screening tool in identifying difficult embryo transfers (ets) without doing a mock et.

so far there has never been a screening tool to identify difficult ets without doing a mock et. this is a prospective, longitudinal study including at least 200 ets. all women undergo a speculum examination at the time of transvaginal oocyte pick-up (opu), the screening questionnaire will be filled by the physician doing the opu procedure. on the day of real et, the physician doing the et will be blinded for the screening result, and fill a second questionnaire after the et. combined with the embryologist recorded parameters, this second questionnaire will be used to categorize ets as difficult or normal. participants will not undergo any procedures beyond their routine treatment. once the targeted number of participants are recruited, the questionnaires will be matched to see the accuracy of the screening questionnaire to identify difficult ets. identification of difficult ets with a non-invasive, free of cost questionnaire can enable selective mock transfers and facilitate the real et for patients, who would otherwise be only recognized on the day of real et, after their embryos have been already thawed for transfer.

Eligibility criteria:
inclusion criteria: * all women undergoing an et is eligible. exclusion criteria: * no exclusion criteria, women can participate with multiple et procedures.

Keywords: infertility embryo transfer
a phase i trial of 4scar19 cells in the treatment of relapsed and refractory b cell leukemia

Conditions: B Acute Lymphoblastic Leukemia

Summary: a chimeric antigen receptor gene-modified t cells (cart: 4scar19)by targeted the cd19 (cluster of differentiation antigen 19), treat patients with cd19 positive malignant b cells tumor, assess treatment safety, and observe therapeutic effects. at the same time,the change process of the cart and residual tumor status of the patient are observe dynamically， which summarizes the best therapeutic effect.


Eligibility criteria:
inclusion criteria: * patients aged more than 6 months. * the immune phenotype analysis of patients with malignant b cell surface expression cd19 molecules. * the karnofsky performance status score over 80 points, is expected to patients survival time is more than 3 months. * the important viscera function meet: heart ultrasound tip heart ejection fraction 50% or higher, electrocardiogram (ecg) not seen obvious abnormality;the blood oxygen saturation 90% or higher;creatinine 2.5 times normal range or less; aspartate aminotransferase and aspartate aminotransferase3 times normal range or less, total bilirubin of 2.0 mg/dl or less. * or greater hgb 80 g/l. * no contraindications to solid and cell separation * the patient and family to have a strong willingness to participate in clinical trials, and are willing to bear all the consequence caused by the test failed, and sign the informed consent. * the panel discussion, combined with patient general condition, think the benefit is greater than the risks involved in the clinical trials. exclusion criteria: * accompanied with other active disease, the treatment is difficult to correct. * bacteria, fungus, or virus infection, unable to control. * people living with hiv. * active hepatitis b virus and hepatitis c virus infection. * of pregnancy and nursing mothers. * before entering the test of the use of glucocorticoid systemic treatment within a week. * confirmed before used car - but invalid patients treated t cells, after in the physical examination, experts discuss confirmed by a team doesn't fit in the car again - t treatment.before used gene therapy method. * the researchers believe that might increase risk subjects or interfere with the test results of any situation.

Keywords: 4s car-t19 b cell leukemia b-all
a clinical study of nly01 in patient's with early parkinson's disease

Conditions: Parkinson Disease

Summary: this is a phase 2 study designed to assess the safety, tolerability and efficacy of nly01 in subjects with early untreated parkinson's disease (pd). evidence suggests nly01, a pegylated form of exenatide, may be beneficial in pd and is being developed as a potential treatment for neurodegenerative disorders.


Eligibility criteria:
inclusion criteria: * patients who are diagnosed with parkinson's disease according to uk parkinson's disease society brain bank clinical diagnostic criteria or movement disorder society research criteria * patients with parkinson's disease according to protocol specified scale assessments * datscan consistent with diagnosis of parkinson's disease * men or women 30 to 80 years of age exclusion criteria: * diagnosis of secondary or atypical parkinsonism * prior use of dopaminergic treatment or mao-b inhibitors for more than 28 days * medical or recreational use of marijuana or thc-containing compounds within 3 months of screening visit * pregnant or planning to become pregnant * metabolic, surgical, psychiatric or laboratory abnormality that would interfere with study compliance or safety in the judgment of the investigator
study on the impact of triptolide woldifiion on hiv-1 reservoir in acute hiv-1 infection

Conditions: AIDS/HIV PROBLEM

Summary: this study is a prospective trial which will recruit 18 patients in acute hiv-1 infection phase. this study aims to evaluate the effects and side effects of arv treatment in chinese patients in acute hiv-1 infection phase, and to evaluate the impact of triptolide wilfordii on hiv-1 reservoir.

two arms will be enrolled in this study, 18 naive-treatment chinese patients in acute hiv-1 infection phase would be allocated to two arms, and treated with the antiretroviral drugs (tenofovir plus lamivudine plus lopinavir / ritonavir plus raltegravir). six months later, 12 patients will be treated with triplitode, in order to observe the impact of of triptolide wilfordii on hiv-1 reservoir of patients in acute infection phase. all patients should be explored for 18 months in terms of the clinical features, drugs side-effects, and immunological and viral response, and the hiv-1 reservoir. we hypothesis that triptolide wilfordii might further reduce the hiv-1 reservoir. the result would provide proofs for further practical antiviral therapy for patients in acute infection phase in china or other resource limited countries.

Eligibility criteria:
inclusion criteria: * • age between 18-65 years * hiv seropositive and confirmed by western blot, confirmed as acute hiv-1 infection * good adherence and follow up in the same place * inform consent signed * art-naïve exclusion criteria: * active opportunistic infection (not stable within 4 weeks 2 weeks ) or aids-related carcinoma; * hemoglobin (hgb) \ 1.5x uln 、 alt or ast or alkaline phosphatase (alp) \>3x upper limit of normal (uln) 、 total bilirubin (tbil) \>2x uln 、 creatine kinase (ck) \> 2x uln; * pregnant or breastfeeding woman or woman with pregnancy plan; * active drug-user;severe neurological defects; * active alcohol abuse; * severe gastrointestinal ulcer . * end-stage disease such as cirrhosis, chronic obstructive pulmonary disease, congestive heart failure, recent myocardial ischemia,tumor, etc * those who are undertaking steroids, immunomodulator, anti-inflammatory agents

Keywords: triptolide wilfordii hiv-1 reservoir acute hiv infection
muscle strength and exercise capacity in sarcoidosis patients

Conditions: Sarcoidosis

Summary: the aim of this study is to examine exercise capacity, muscle strength and fatigue in sarcoidosis. in this longitudinal study the changes in prevalence of exercise intolerance, reduced muscle strength and fatigue will be established in a two-year follow-up. also the relation between these physical impairments in time and other clinical parameters, such as qol, will be established.

the aim of this study is to examine exercise capacity, muscle strength and fatigue in sarcoidosis. in this longitudinal study the changes in prevalence of exercise intolerance, reduced muscle strength and fatigue will be established in a two-year follow-up. also the relation between these physical impairments in time and other clinical parameters, such as qol, will be established. study design: sarcoidosis patients referred to the ild care team of outpatient clinic of the department of respiratory medicine of the mumc and also participated in the baseline study between november 2008 and september 2009 will be included in this longitudinal study. a six-minute walk test and peripheral muscle strength measurements (included in the regular clinical work-up of sarcoidosis patients) will be performed under supervision of a physical therapist at the department of physical therapy of the mumc. moreover, the patients will be asked to complete the whoqol-bref questionnaire and the fatigue assessment scale. a maximum of 124 patients will be included.

Eligibility criteria:
inclusion criteria: * diagnosed sarcoidosis according to wasog/ats/ers guidelines exclusion criteria: * not being able to walk

Keywords: sarcoidosis muscle strength exercise intolerance qol